EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
17 May 2018 - 6:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage, specialty pharmaceutical company with
two proprietary platform technologies for treating diseases and
disorders of the eye, today announced that Steven Boyd has joined
its board.
Paul Chaney, EyeGate’s Chairman, said, “We are pleased to
welcome Steven Boyd to the Board of EyeGate. Steven brings a wealth
of experience in advising small-cap biopharmaceutical companies and
will be a valuable addition to the Board. We look forward to
working with him as we grow the company.”
Mr. Boyd said, “I am excited to join the Board of a company like
EyeGate with two unique and proprietary platforms that I strongly
believe in. EyeGate has several upcoming milestones and I look
forward to working with EyeGate’s management and the other members
of the Board to determine the best way to unlock shareholder
value.”
Mr. Boyd is the Chief Investment Officer of Armistice Capital
(“Armistice”), a long-short equity hedge fund focused on the health
care and consumer sectors based in New York City. Previously, Mr.
Boyd had been a Research Analyst at Senator Investment Group, York
Capital, and SAB Capital Management, where he focused on health
care. Mr. Boyd began his career as an Analyst at McKinsey &
Company. Mr. Boyd has served as a member of the board of
directors of Cerecor Inc., an integrated biopharmaceutical company
focused on pediatric healthcare, since April 2017. Mr. Boyd
received a B.S. in Economics as well as a B.A. in Political Science
from The Wharton School of the University of Pennsylvania.
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company
focused on developing and commercializing products using its two
proprietary platform technologies for treating diseases and
disorders of the eye.
EyeGate’s CMHA-S platform is based on a cross-linked thiolated
carboxymethyl hyaluronic acid (CMHA-S), a modified form of the
natural polymer hyaluronic acid (HA), which is a gel that possesses
unique physical and chemical properties such as hydrating and
healing when applied to the ocular surface. The ability of CMHA-S
to adhere longer to the ocular surface, resist degradation and
protect the ocular surface makes it well-suited for treating
various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials,
incorporates a reformulated, topically active corticosteroid,
Dexamethasone Phosphate, that is delivered into the ocular tissues
through EyeGate’s proprietary innovative drug delivery system, the
EyeGate II Delivery System. For more information, please visit
www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page,
corporate Twitter account, and LinkedIn page as channels of
distribution of information about EyeGate and its product
candidates. Such information may be deemed material information,
and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor EyeGate’s website and its social media accounts in addition
to following its press releases, SEC filings, public conference
calls, and webcasts. The social media channels that EyeGate intends
to use as a means of disclosing the information described above may
be updated from time to time as listed on EyeGate’s investor
relations website.
Forward-looking Statements
Some of the statements in this press release are
“forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product and those
of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate,
as well as the success thereof, with such approvals or success may
not be obtained or achieved on a timely basis or at all. These
statements involve risks and uncertainties that may cause results
to differ materially from the statements set forth in this press
release, including, among other things, certain risk factors
described under the heading “Risk Factors” contained in EyeGate’s
Annual Report on Form 10-K filed with the SEC on March 2, 2018 or
described in EyeGate’s other public filings. EyeGate’s results may
also be affected by factors of which EyeGate is not currently
aware. The forward-looking statements in this press release speak
only as of the date of this press release. EyeGate expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in
its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is
based.
Contact
Joseph Green / Andrew Gibson
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030 / 7019
jgreen@edisongroup.com / agibson@edisongroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2024 to May 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From May 2023 to May 2024